MX2023011655A - Inhibidores terapeuticos de la se?alizacion de gdf15. - Google Patents
Inhibidores terapeuticos de la se?alizacion de gdf15.Info
- Publication number
- MX2023011655A MX2023011655A MX2023011655A MX2023011655A MX2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A MX 2023011655 A MX2023011655 A MX 2023011655A
- Authority
- MX
- Mexico
- Prior art keywords
- gdf15
- signalling
- gfral
- relates
- therapeutic inhibitors
- Prior art date
Links
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 229940124788 therapeutic inhibitor Drugs 0.000 title 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 102100040304 GDNF family receptor alpha-like Human genes 0.000 abstract 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 1
- 101001038371 Homo sapiens GDNF family receptor alpha-like Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Esta invención se refiere a anticuerpos que se unen a e inhiben la actividad de la proteína receptora similar a alfa de la familia del factor neurotrófico derivado de las células gliales (GFRAL). La invención también se refiere a la ruta de señalización GDF15-GFRAL como una diana terapéutica para estados de caquexia y afecciones que implican una reducción de la toma de alimentos y reducción en la masa muscular y grasa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104556.2A GB202104556D0 (en) | 2021-03-31 | 2021-03-31 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2107331.7A GB202107331D0 (en) | 2021-05-21 | 2021-05-21 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2108170.8A GB202108170D0 (en) | 2021-06-08 | 2021-06-08 | Theraputic inhibitors of GDF15 Signalling |
| PCT/EP2022/058669 WO2022207846A1 (en) | 2021-03-31 | 2022-03-31 | Therapeutic inhibitors of gdf15 signalling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011655A true MX2023011655A (es) | 2023-10-11 |
Family
ID=81580347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011655A MX2023011655A (es) | 2021-03-31 | 2022-03-31 | Inhibidores terapeuticos de la se?alizacion de gdf15. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182585A1 (es) |
| EP (1) | EP4314071A1 (es) |
| JP (1) | JP2024511853A (es) |
| KR (1) | KR20230165285A (es) |
| AU (1) | AU2022251923A1 (es) |
| BR (1) | BR112023020152A2 (es) |
| CA (1) | CA3215737A1 (es) |
| CO (1) | CO2023013791A2 (es) |
| IL (1) | IL307382A (es) |
| MX (1) | MX2023011655A (es) |
| WO (1) | WO2022207846A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201807279QA (en) | 2016-03-31 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| IT202300006387A1 (it) * | 2023-03-31 | 2024-10-01 | Univ Degli Studi Roma La Sapienza | Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| PL2441466T3 (pl) | 2004-04-13 | 2015-01-30 | St Vincents Hospital Sydney Ltd | Środek hamujący MIC-1 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| BR112012014022A2 (pt) | 2009-12-11 | 2017-04-04 | Genecode As | composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| JP2015532271A (ja) | 2012-09-26 | 2015-11-09 | ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ | 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体 |
| EP3689370A1 (en) | 2012-12-21 | 2020-08-05 | Aveo Pharmaceuticals Inc. | Anti-gdf15 antibodies |
| LT3653644T (lt) | 2014-03-26 | 2024-01-25 | Julius-Maximilians-Universität Würzburg | Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą |
| EP3197493B1 (en) | 2014-09-25 | 2021-03-10 | Aveo Pharmaceuticals Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| BR112018006218A2 (pt) | 2015-10-02 | 2018-10-09 | Univ Wuerzburg J Maximilians | iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15 |
| WO2017121865A1 (en) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
| CN108697795A (zh) | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral受体疗法 |
| EP3423097A4 (en) | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT |
| SG11201807279QA (en) | 2016-03-31 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US11312766B2 (en) | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
-
2022
- 2022-03-31 JP JP2023560403A patent/JP2024511853A/ja active Pending
- 2022-03-31 US US18/284,952 patent/US20240182585A1/en active Pending
- 2022-03-31 BR BR112023020152A patent/BR112023020152A2/pt unknown
- 2022-03-31 IL IL307382A patent/IL307382A/en unknown
- 2022-03-31 EP EP22720935.0A patent/EP4314071A1/en active Pending
- 2022-03-31 AU AU2022251923A patent/AU2022251923A1/en active Pending
- 2022-03-31 KR KR1020237037287A patent/KR20230165285A/ko active Pending
- 2022-03-31 CA CA3215737A patent/CA3215737A1/en active Pending
- 2022-03-31 MX MX2023011655A patent/MX2023011655A/es unknown
- 2022-03-31 WO PCT/EP2022/058669 patent/WO2022207846A1/en not_active Ceased
-
2023
- 2023-10-19 CO CONC2023/0013791A patent/CO2023013791A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4314071A1 (en) | 2024-02-07 |
| BR112023020152A2 (pt) | 2023-11-14 |
| CO2023013791A2 (es) | 2024-01-25 |
| US20240182585A1 (en) | 2024-06-06 |
| IL307382A (en) | 2023-11-01 |
| AU2022251923A1 (en) | 2023-11-16 |
| KR20230165285A (ko) | 2023-12-05 |
| CA3215737A1 (en) | 2022-10-06 |
| JP2024511853A (ja) | 2024-03-15 |
| WO2022207846A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011655A (es) | Inhibidores terapeuticos de la se?alizacion de gdf15. | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| EA201290589A1 (ru) | Cd127-связывающие белки | |
| GEP20125471B (en) | Compositions monovalent for cd40l binding and methods of use | |
| EP4385520A3 (en) | Glycotargeting therapeutics | |
| EA201490393A1 (ru) | Соматотропный гормон пролонгированного действия и способы его получения | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| MX2017006639A (es) | Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso. | |
| NZ759601A (en) | Aggrecan binding immunoglobulins | |
| RU2017142932A (ru) | Фармацевтические и пищевые композиции для индуцирования насыщения и продления сытости у нуждающихся в этом субъектов | |
| BR112022010231A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l | |
| EP4408881A4 (en) | ANTIBODIES AGAINST THE SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF | |
| PL4230650T3 (pl) | Przeciwciała zdolne do wiązania się z białkiem kolca koronawirusa sars-cov-2 | |
| MX2025006615A (es) | Metodos para alterar la composicion corporal | |
| EA201691436A1 (ru) | Композиция, включающая окру для применения в уменьшении абсорбции пищевого жира | |
| PH12022553099A1 (en) | Anti-cd200r1 antibodies and methods of use thereof | |
| MX2020004397A (es) | Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares. | |
| IL290509A (en) | Antibodies that bind to lrp5 proteins and methods of use | |
| WO2010034514A3 (de) | Cfhr1 als inhibitor der c5 konvertase zur behandlung von autoimmunerkrankungen | |
| IL315020A (en) | Antibodies capable of binding to the spike protein of the SARS-COV-2 coronavirus | |
| Inubushi et al. | Lactoferrin inhibits infection-related osteoclastogenesis without interrupting compressive force-related osteoclastogenesis | |
| MX2021005908A (es) | Análogos de gdf15 y métodos para usarlos en la disminución del peso corporal y/o la reducción de la ingesta de alimentos. | |
| Pang et al. | Sarcopenia and nonalcoholic fatty liver disease: New evidence for low vitamin D status contributing to the link | |
| MX2024001644A (es) | Anticuerpos contra el receptor alfa de la interleucina-4 humana. | |
| RU2013147976A (ru) | ИНГИБИТОРЫ Trmp5 ПОДДЕРЖИВАЮТ СНИЖЕНИЕ МАССЫ ТЕЛА БЕЗ УМЕНЬШЕНИЯ ПОТРЕБЛЕНИЯ ПИЩИ |